MXPA04004173A - Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina. - Google Patents

Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.

Info

Publication number
MXPA04004173A
MXPA04004173A MXPA04004173A MXPA04004173A MXPA04004173A MX PA04004173 A MXPA04004173 A MX PA04004173A MX PA04004173 A MXPA04004173 A MX PA04004173A MX PA04004173 A MXPA04004173 A MX PA04004173A MX PA04004173 A MXPA04004173 A MX PA04004173A
Authority
MX
Mexico
Prior art keywords
controlled release
reducing
release forms
oral controlled
forms useful
Prior art date
Application number
MXPA04004173A
Other languages
English (en)
Inventor
Cuong Quoc An
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MXPA04004173A publication Critical patent/MXPA04004173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Abstract

La presente invencion provee nuevas formulaciones de dosis oral que comprenden un agente activo de nicotina, opcionalmente combinado con un antidepresivo que, a traves de la liberacion controlada del ingrediente o ingredientes activos alivia algunos de los sintomas de abstinencia de nicotina que una persona puede experimentar durante los intentos para dejar de fumar.
MXPA04004173A 2001-11-02 2002-10-28 Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina. MXPA04004173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33635301P 2001-11-02 2001-11-02
PCT/US2002/034576 WO2003039518A1 (en) 2001-11-02 2002-10-28 Oral controlled release forms useful for reducing or preventing nicotine cravings

Publications (1)

Publication Number Publication Date
MXPA04004173A true MXPA04004173A (es) 2004-09-06

Family

ID=23315697

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004173A MXPA04004173A (es) 2001-11-02 2002-10-28 Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.

Country Status (11)

Country Link
US (1) US20040037879A1 (es)
EP (1) EP1450768A1 (es)
JP (1) JP2005511588A (es)
CN (1) CN1822819A (es)
AR (1) AR037183A1 (es)
AU (1) AU2002340318B2 (es)
CA (1) CA2465496A1 (es)
MX (1) MXPA04004173A (es)
NZ (1) NZ532518A (es)
TW (1) TW200302741A (es)
WO (1) WO2003039518A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138399A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US8256433B2 (en) * 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US20080138398A1 (en) * 1999-07-16 2008-06-12 Aradigm Corporation Dual release nicotine formulations, and systems and methods for their use
US20080138294A1 (en) * 1999-07-16 2008-06-12 Igor Gonda Systems and methods for effecting cessation of tobacco use
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
DK1803444T3 (en) * 2002-12-20 2019-02-25 Niconovum Ab PROCEDURE FOR PREPARING A NICOTIC PARTICULATE MATERIAL WITH A CRYSTALLINE CELLULOSE (ESPECIALLY MCC)
PL1648421T3 (pl) * 2003-07-24 2018-03-30 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
MEP3608A (en) * 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
EP1802258A4 (en) 2004-09-13 2015-09-23 Chrono Therapeutics Inc BIOSYNCHRONE TRANSDERMAL MEDICINES
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US9198448B2 (en) * 2005-02-07 2015-12-01 Intercontinental Great Brands Llc Stable tooth whitening gum with reactive ingredients
ATE446023T1 (de) 2005-04-29 2009-11-15 Philip Morris Prod Tabakbeutelprodukt
US9044049B2 (en) * 2005-04-29 2015-06-02 Philip Morris Usa Inc. Tobacco pouch product
US7901717B1 (en) * 2005-06-03 2011-03-08 Scientific Food Solutions, Llc Alkalizing compositions and methods for using the same
CA2629954A1 (en) * 2005-11-15 2007-05-24 Wm. Wrigley Jr. Company Methods of producing coated products including active agent and products regarding same
US8685478B2 (en) 2005-11-21 2014-04-01 Philip Morris Usa Inc. Flavor pouch
BRPI0708068A2 (pt) * 2006-02-17 2011-05-17 Novartis Ag pelìculas bucais passíveis de desintegração
US20070269386A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20070269492A1 (en) 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
JP2010504931A (ja) 2006-09-27 2010-02-18 ニコノヴァム エービー 指向性の使用
EP2086317A4 (en) * 2006-12-01 2010-03-03 Aradigm Corp NICOTINE FORMULATIONS, KITS AND SYSTEMS AND METHOD FOR THEIR USE
US8616221B2 (en) 2007-02-28 2013-12-31 Philip Morris Usa Inc. Oral pouch product with flavored wrapper
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US8067046B2 (en) * 2007-06-08 2011-11-29 Philip Morris Usa Inc. Oral pouch product including soluble dietary fibers
US9888712B2 (en) * 2007-06-08 2018-02-13 Philip Morris Usa Inc. Oral pouch products including a liner and tobacco beads
WO2009010881A2 (en) * 2007-07-16 2009-01-22 Philip Morris Products S.A. Oral pouch products with immobilized flavorant particles
WO2009010876A2 (en) 2007-07-16 2009-01-22 Philip Morris Products S.A. Oral pouch product having soft edge and method of making
WO2009010884A2 (en) 2007-07-16 2009-01-22 Philip Morris Products S.A. Tobacco-free oral flavor delivery pouch product
WO2009010878A2 (en) * 2007-07-16 2009-01-22 Philip Morris Products S.A. Method of flavor encapsulation of oral pouch products through the use of a drum coater
US8202589B2 (en) * 2007-07-16 2012-06-19 Philip Morris Usa Inc. Oral delivery pouch product with coated seam
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CA2702055C (en) * 2007-10-10 2017-12-12 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US9125434B2 (en) 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
MX2010003928A (es) 2007-10-11 2010-09-10 Philip Morris Prod Producto de tabaco sin humo.
MY149720A (en) * 2007-12-21 2013-10-14 Swedish Match North Europe Ab A tobacco or non-tobacco product comprising magnesium carbonate
FR2926221A1 (fr) * 2008-01-14 2009-07-17 Tassin Thomas Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand.
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
PT2361081T (pt) 2008-10-14 2016-09-05 Mcneil Ab Forma de dosagem intra-oral multiporção e seu uso
US8377215B2 (en) * 2008-12-18 2013-02-19 Philip Morris Usa Inc. Moist botanical pouch processing
US9027567B2 (en) * 2008-12-30 2015-05-12 Philip Morris Usa Inc. Oral pouch product with multi-layered pouch wrapper
US8863755B2 (en) * 2009-02-27 2014-10-21 Philip Morris Usa Inc. Controlled flavor release tobacco pouch products and methods of making
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US8747562B2 (en) * 2009-10-09 2014-06-10 Philip Morris Usa Inc. Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
CA2796346C (en) 2010-04-14 2018-10-02 Altria Client Services Inc. Preformed smokeless tobacco product
KR20130067255A (ko) * 2010-04-27 2013-06-21 노파르티스 아게 경구 투여 형태
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
SE535587C2 (sv) * 2011-03-29 2012-10-02 Chill Of Sweden Ab Produkt innehållande ett fritt nikotinsalt och en ej vattenlöslig påse
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) * 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
FR2993778B1 (fr) * 2012-07-30 2016-06-17 Pf Medicament Pastilles a cinetiques multiples de liberation de principes actifs
US10799548B2 (en) 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
WO2015068058A1 (en) 2013-11-06 2015-05-14 Rk Technology & Investments Pte. Ltd. Tobacco free 'niconuts'and the process thereof
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
CN106578316A (zh) * 2016-12-20 2017-04-26 大连丹特生物技术有限公司 一种烟碱木糖醇口香糖及其制备方法
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited DRUG DELIVERY METHODS AND SYSTEMS
US11679081B2 (en) 2018-07-13 2023-06-20 Mcneil Ab Chewing gum comprising nicotine
US11353469B2 (en) * 2019-06-05 2022-06-07 Hall Labs Llc Nontoxic compounds for use as taggants in nutritional and pharmaceutical products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
EP4090314A1 (en) * 2020-01-15 2022-11-23 McNeil AB Lozenge
CN112220756B (zh) * 2020-10-16 2023-06-13 重庆市义力医药科技有限公司 一种尼古丁颗粒组合物及其制备方法
CN112220757B (zh) * 2020-10-16 2022-05-27 重庆市义力医药科技有限公司 一种尼古丁颗粒组合物及其制备方法及其制备装置
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
US20220312830A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Nicotine-containing agglomerates and methods of forming the same
CN113208156B (zh) * 2021-05-07 2022-08-12 云南中烟工业有限责任公司 一种基于柠檬酸尼古丁盐胶凝剂的载香超分子凝胶
CN113180282B (zh) * 2021-05-07 2022-08-19 云南中烟工业有限责任公司 一种基于外消旋酒石酸尼古丁盐胶凝剂的载香超分子凝胶

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5702723A (en) * 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US6300343B1 (en) * 1998-06-16 2001-10-09 Smithkline Beecham Corporation Method of treatment
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
AR037183A1 (es) 2004-10-27
AU2002340318B2 (en) 2007-11-15
TW200302741A (en) 2003-08-16
EP1450768A1 (en) 2004-09-01
WO2003039518A1 (en) 2003-05-15
US20040037879A1 (en) 2004-02-26
JP2005511588A (ja) 2005-04-28
CA2465496A1 (en) 2003-05-15
NZ532518A (en) 2006-04-28
CN1822819A (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
MXPA04004173A (es) Formas orales de liberacion controlada utiles para la reduccion o prevencion de la ansiedad hacia la nicotina.
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
MXPA05002942A (es) Forma de dosificacion oral de liberacion modificada.
HK1064921A1 (en) Sustained release formulations of oxymorphone
MY127290A (en) New use of flibanserin
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
MXPA03008762A (es) Forma de dosificacion oral que contiene nicotina.
SE0102276D0 (sv) Device and method for the administration of a medicament
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
MX2007000008A (es) Formas farmaceuticas orales, protegidas frente al abuso, que contienen (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil) fenol.
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA05010196A (es) Nuevas formulaciones y su uso.
MXPA02006603A (es) Forma de dosificacion de nucleo suave, de revestimiento fragil.
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
JP2002542281A5 (es)
MXPA05010161A (es) Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias.
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
IL159789A0 (en) Active ingredient combination for pharmacological therapy of nicotine dependence
EP1260221A3 (en) Combination treatment for depression and anxiety
MXPA04001812A (es) Nueva forma de dosificacion oral de liberacion prolongada.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal